Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03966911 · ClinicalTrials.gov registry record · NA
Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 335
- Enrollment target
NCT03966911: Completed NA study, sponsored by Medtronic MiniMed.
NCT03966911 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 335 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03966911, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 335 participants
- Enrollment target
Study Summary
The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
Primary Outcome
Mean of daily percentage of sensor values within 20% of Yellow Springs Instrument (YSI™\*) reference value (within 20 mg/dL if sensor values \< 80 mg/dL), across all participants and all Frequent Sample Testing (FST) days. Note Self-Monitoring Blood Glucose (SMBG) was used for age 2-6, instead of YSI.
Interventions
- DEVICE Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2019-06-14 |
| Est. Completion | 2020-05-13 |
| Phase | NA |
What the finished NCT03966911 record still lists
NCT03966911 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter is the first listed.
NCT03966911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03966911 about?
NCT03966911 is a clinical study titled "Performance Evaluation of an Advanced Algorithm With CGM in Adults, Adolescents, and Pediatrics". The purpose of this study is to demonstrate the performance of the Guardian™ Sensor (3) with an advanced algorithm in subjects age 2 - 80 years, for the span of 170 hours (7 days).
What is the current status of trial NCT03966911?
This trial is currently completed. It is a NA study. The enrollment target is 335 participants. The study started on 2019-06-14. Estimated completion is 2020-05-13.
What interventions are being tested in trial NCT03966911?
The interventions under investigation include: Guardian™ Sensor (3) connected to a Guardian™ Connect Transmitter (DEVICE).
Who is sponsoring clinical trial NCT03966911?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03966911's enrollment target sits among peer trials
335 305th of 2000 higher than 1,696 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI